Prognostic significance of HER-2/neu expression in patients with ductal carcinoma in situ

Israel Medical Association Journal

Volumn 12, Issue 5, 2010, Pages 290-295

  Stackievicz, Rodica ^a,b   Paran, Haim ^a,b   Bernheim, Joelle ^a   Shapira, Mayra ^a,b   Weisenberg, Neomy ^a,b   Kaufman, Tzvi ^a,b   Klein, Ehud ^a,b   Gutman, Mordechai ^a,b  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Ductal carcinoma in situ; Her 2 neu; Markers; Prognosis; Recurrence

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAMOXIFEN; GENETIC MARKER;

ADJUVANT THERAPY; ADULT; AGED; BONE METASTASIS; BREAST CALCIFICATION; BREAST NECROSIS; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL RECORD REVIEW; METASTASIS POTENTIAL; PARTIAL MASTECTOMY; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; REVIEW; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; GENE EXPRESSION; GENETIC MARKER; GENETICS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PREDICTIVE VALUE; PROTO ONCOGENE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; GENES, ERBB-2; GENETIC MARKERS; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 77953503334     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Ottesen GL. Carcinoma in situ of the female breast. A clinico-pathologic, immunohistological, and DNA ploidy study. APMIS Suppl 2003; 108: 1-67.
2. Badve S, A'hern RP, Ward AM, et al. Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: a comparative study with long-term follow-up. Hum Pathol 1998; 29: 915-923.
3. Sneige N, McNeese MD, Atkinson EN, et al. Ductal carcinoma in situ treated with lumpectomy and irradiation: histopathological analysis of 49 specimens with emphasis on risk factors and long term results. Hum Pathol 1995; 26: 642-649.
4. Fisher B, Constantino J, Redmond C, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993; 328: 1581-1586.
5. Solin LJ, Kurtz J, Fourquet A, et al. Fifteen years results of breast conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 1996; 14: 54-63.
6. Ottesen GL, Graversen HP, Blichert-Toft M, Zedeler K, Andersen JA. Ductal carcinoma in situ of the female breast. Short term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group. Am J Surg Pathol 1992; 16: 1183-1196.
7. Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification of ductal carcinoma in situ. Lancet 1995; 345: 1154-1157.
8. Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999; 13: 1455-1461.
9. Gasparini G, Gullick WJ, Sainsbury RC, Meli S, Boracchi P, Pozza F. Prognostic significance of the cerb B2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 1992; 10: 686-695.
10. Ross JS, Fletcher JA, Linette GP, et al. The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003; 8: 307-325.
11. Rodriques NA, Dillon D, Carter D, Parisot N, Hafly BG. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women. Cancer 2003; 97: 1393-1403.
12. Claus EB, Chu P, Howe CL, Davison TL, Stern DC, DiGiovana MP. Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors. Exp Mol Pathol 2001; 70:303-316.
13. Hoque A, Sneige N, Sahin AA, Menter DG, Bacus JW, Lippman Sm. HER-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol Biomark Prev 2002; 11: 587-590.
14. Ringberg A, Anagnostaki L, Anderson H, Idvall I, Ferno M. Cell biological factors in ductal carcinoma in situ (DCIS) of the breast - relationship to ipsilateral local recurrence and histopathological characteristics. Eur J Cancer 2001; 37: 1514-1522.
15. Lebeau A, Unholzer A, Amman G, Kronawitter M, Bauerfeind I, Lohrs U. EGFR, HER-2/neu, cyclin D1, p21, and p53 in correlation to cell proliferation and steroid receptor status in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 2003; 79: 187-198.
16. Rudas M, Neumayer R, Gnant MF, Mittelbock M, Jakesz R, Reiner A. P53, protein expression, cell proliferation, and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Eur J Cancer 1997; 33: 39-44.
17. Cornfield DB, Palazzo JP, Schwartz GF, et al. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast. Cancer 2004; 100: 2317-2327.
18. Roka S, Rudas M, Taucher S, et al. High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. Eur J Surg Oncol 2004; 30: 243-247.
19. Tan PH, Chuan KL, Chiang G, Wrong CY, Dong F, Bay BH. Correlation of p53 and cerb B2 expression and hormonal receptor status with clinicopathologic parameters in ductal carcinoma in situ of the breast. Oncol Rep 2002; 9: 1081-1086.
20. Stern DF, Heffernan PA, Weinberg RA. P185, a product of the neu proto-oncogene, is a receptor-like protein associated with tyrosine kinase activity. Moll Cell Biol 1986; 6: 1729-1740.
21. Fischer B, Redmond C, Poisson R, et al. Eight year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989; 320: 822-828.
22. Perin T, Canzonieri V, Massarut S, et al. Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast. Eur J Cancer 1996; 32A: 1148-1155.
23. Bonnier P, Body G, Bessenay F, et al. Prognostic factors in ductal carcinoma in situ of the breast: results of a retrospective study of 575 cases. The Association for Research in Oncologic Gynecology. Eur J Obstet Gynecol Reprod Biol 1999; 84: 27-35.
24. Boyages J, Delaney G, Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer 1999: 85: 616-28.